瑞戈非尼在结直肠癌和胃肠道间质瘤中的评估。 - Suppr

Suppr

超能文献

Evaluation of regorafenib in colorectal cancer and GIST.

作者信息

Waddell Tom, Cunningham David

机构信息

Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.

出版信息

Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

DOI:10.1016/S0140-6736(12)62006-6

PMID:23177516

Abstract

摘要

相似文献

Evaluation of regorafenib in colorectal cancer and GIST.

Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.

Oncology (Williston Park). 2012 Nov;26(11):1072.

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.

Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.

Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.

BioDrugs. 2013 Oct;27(5):525-31. doi: 10.1007/s40259-013-0061-2.

[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].

Nihon Rinsho. 2012 Nov;70 Suppl 8:452-6.

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

Oncology (Williston Park). 2009 Jan;23(1):65-6.

Current management of GISTs.

Clin Adv Hematol Oncol. 2010 May;8(5):334.

Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.

J Cancer Res Ther. 2011 Oct-Dec;7(4):491-3. doi: 10.4103/0973-1482.92014.

Hits and misses in targeting pediatric cancers.

Pediatr Blood Cancer. 2009 Jul;52(7):751-2. doi: 10.1002/pbc.21937.

引用本文的文献

Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.

AAPS PharmSciTech. 2024 Jan 24;25(1):23. doi: 10.1208/s12249-024-02734-9.

Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.

Medicine (Baltimore). 2023 Dec 15;102(50):e36435. doi: 10.1097/MD.0000000000036435.

Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema.

Exp Mol Med. 2023 Apr;55(4):794-805. doi: 10.1038/s12276-023-00966-6. Epub 2023 Apr 3.

Advances in 3D Vascularized Tumor-on-a-Chip Technology.

Adv Exp Med Biol. 2022;1379:231-256. doi: 10.1007/978-3-031-04039-9_9.

Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment.

Nat Commun. 2021 Feb 3;12(1):759. doi: 10.1038/s41467-021-21071-0.

Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.

Int J Mol Sci. 2020 Nov 3;21(21):8232. doi: 10.3390/ijms21218232.

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility.

Cancers (Basel). 2019 Jun 7;11(6):787. doi: 10.3390/cancers11060787.

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.

Oncotarget. 2017 Sep 30;8(61):103465-103476. doi: 10.18632/oncotarget.21403. eCollection 2017 Nov 28.

An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Int J Genomics. 2015;2015:179528. doi: 10.1155/2015/179528. Epub 2015 Sep 2.

Management of regorafenib-related toxicities: a review.

Therap Adv Gastroenterol. 2015 Sep;8(5):285-97. doi: 10.1177/1756283X15580743.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluation of regorafenib in colorectal cancer and GIST.

作者信息

Waddell Tom, Cunningham David

机构信息

Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.

出版信息

Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

DOI:10.1016/S0140-6736(12)62006-6

PMID:23177516

Abstract

摘要

相似文献

Evaluation of regorafenib in colorectal cancer and GIST.

Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.

Oncology (Williston Park). 2012 Nov;26(11):1072.

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.

Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.

Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.

BioDrugs. 2013 Oct;27(5):525-31. doi: 10.1007/s40259-013-0061-2.

[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].

Nihon Rinsho. 2012 Nov;70 Suppl 8:452-6.

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

Oncology (Williston Park). 2009 Jan;23(1):65-6.

Current management of GISTs.

Clin Adv Hematol Oncol. 2010 May;8(5):334.

Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.

J Cancer Res Ther. 2011 Oct-Dec;7(4):491-3. doi: 10.4103/0973-1482.92014.

Hits and misses in targeting pediatric cancers.

Pediatr Blood Cancer. 2009 Jul;52(7):751-2. doi: 10.1002/pbc.21937.

引用本文的文献

Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.

AAPS PharmSciTech. 2024 Jan 24;25(1):23. doi: 10.1208/s12249-024-02734-9.

Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.

Medicine (Baltimore). 2023 Dec 15;102(50):e36435. doi: 10.1097/MD.0000000000036435.

Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema.

Exp Mol Med. 2023 Apr;55(4):794-805. doi: 10.1038/s12276-023-00966-6. Epub 2023 Apr 3.

Advances in 3D Vascularized Tumor-on-a-Chip Technology.

Adv Exp Med Biol. 2022;1379:231-256. doi: 10.1007/978-3-031-04039-9_9.

Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment.

Nat Commun. 2021 Feb 3;12(1):759. doi: 10.1038/s41467-021-21071-0.

Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.

Int J Mol Sci. 2020 Nov 3;21(21):8232. doi: 10.3390/ijms21218232.

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility.

Cancers (Basel). 2019 Jun 7;11(6):787. doi: 10.3390/cancers11060787.

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.

Oncotarget. 2017 Sep 30;8(61):103465-103476. doi: 10.18632/oncotarget.21403. eCollection 2017 Nov 28.

An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Int J Genomics. 2015;2015:179528. doi: 10.1155/2015/179528. Epub 2015 Sep 2.

Management of regorafenib-related toxicities: a review.

Therap Adv Gastroenterol. 2015 Sep;8(5):285-97. doi: 10.1177/1756283X15580743.